In humans, this drug was marketed for women with constipation-predominant or mixed symptom irritable bowel syndrome and demonstrated clear benefits in quality of life and gastrointestinal symptoms but is currently only available in a restricted fashion because of an association with ischemic colitis and cardiovascular disease.